---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-043142"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-11-30T23:59:59+00:00"
generated_at: "2026-06-07T19:52:16.409838+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BriaCell reports new Phase 2 responder with 3-cycle orbital tumor resolution after 7 prior failed regimens

## Summary
- Patient with proptosis from orbital metastatic breast cancer had remarkable improvement and pain reduction after 3 cycles of Bria-IMT combo.
- Heavily pretreated patient had failed 7 prior regimens; continues treatment with well-tolerated regimen.
- Second reported case of orbital tumor resolution; first patient had failed 12 regimens and 16 agents.
- Additional Phase 2 survival updates and clinical data to be presented at San Antonio Breast Cancer Symposium Dec 6-7, 2023.

## SEC filing metadata
- accession: 0001493152-23-043142
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-11-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223043142/0001493152-23-043142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223043142/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-043142
- JSON: https://secwatch.observer/filing/0001493152-23-043142.json
- Plain text: https://secwatch.observer/filing/0001493152-23-043142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.